5 protocol(s) meet the specified criteria
PI: Foster, Matthew
Protocol No.TitleStatus
CALGB10403An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)Open (affiliates only)
CALGB10502Dose Escalation and Phase II Study of Bortezomib (IND #58443, NSC # 681239) Added to Standard Daunorubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 YearsOpen (affiliates only)
CALGB10503Phase II Study of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 YearsOpen (affiliates only)
CP-MGD006-01A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia Open
LCCC1111An Open-Label Dose-Finding Study of Lenalidomide as Consolidation Followed by Lenalidomide Maintenance Therapy for Adults >/= 60 Years of Age with AML in Partial or Complete Response Following Conventional Induction TherapyOpen